Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
small decrease » small increased (Expand Search)
_ largest » _ large (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
small decrease » small increased (Expand Search)
_ largest » _ large (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
13
-
14
Expected marginal mean QoL scores for two age cohorts over 2016–2024 in Gauteng, South Africa.
Published 2025Subjects: -
15
-
16
-
17
-
18
-
19
-
20